Company intelligence / Profile preview

Imvaria

Berkeley, California, USA

Ownership: Private
Development stage: Other

Overview

Imvaria has two FDA-authorized adjunctive AI-based diagnostic tools—ScreenDx for interstitial lung disease (ILD) and Fibresolve for idiopathic pulmonary fibrosis (IPF)—both with integrated CPT billing codes. Fibresolve was the first FDA Breakthrough-Designated AI diagnostic tool for lung fibrosis and shows clinical utility as a non-invasive, supplemental method for risk assessment and diagnosis. Preliminary results for an oncology program (malignancy assessment in chest CTs) have been presented at major conferences, with clinical studies planned.[1][2][4][5]

Therapeutic areas: OncologyPulmonology
Modalities: DeviceSoftware-as-Medical-Device
Industry: Digital Health Medical Devices

Partnerships

Mayo Clinic (AI biomarker development in lung cancer via Mayo Clinic Platform collaboration)Medical Horizons (AI diagnostics distribution in MENA region)

Beyond the preview

Go deeper on Imvaria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imvaria.

Explore the full profile